Cognitive-behavioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: An open trial

Journal of Clinical Psychiatry

Volumn 60, Issue 9, 1999, Pages 584-590

  Simpson, H Blair ^a,b   Gorfinkle, Kenneth S ^b   Liebowitz, Michael R ^a,b  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSPIRONE; CLOMIPRAMINE; CLONAZEPAM; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; HALOPERIDOL; METHYLPHENIDATE; NORCLOMIPRAMINE; NORFLUOXETINE; PAROXETINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADJUVANT THERAPY; ADULT; ARTICLE; BEHAVIOR THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE THERAPY; COMPULSION; DRUG EFFICACY; FEMALE; HUMAN; MALE; MENTAL DISEASE; OBSESSION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; TREATMENT OUTCOME;

EID: 0032843557     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v60n0904     Document Type: Article

References (39)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
2. Robins LN, Helzer JE, Weissman MM, et al. Lifetime prevalence of specific psychiatric disorders in three sites. Arch Gen Psychiatry 1984;41: 949-958
3. Antony MM, Downie F, Swinson RP. Diagnostic issues and epidemiology in obsessive-compulsive disorder. In: Swinson RP, Antony MM, Rachman S, et al, eds. Obsessive-Compulsive Disorder: Theory, Research, and Treatment. New York, NY: Guilford Publications; 1998:3-32
4. Leon AC, Portera L, Weissman MM. The social costs of anxiety disorders. Br J Psychiatry 1995;166(suppl 27):19-22
5. Koran LM, Thienemann ML, Davenport R. Quality of life for patients with obsessive-compulsive disorder. Am J Psychiatry 1996;153:783-788
6. Murray CJ, Lopez AD, eds. The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability From Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. Cambridge, Mass: Harvard University Press; 1996
7. Kozak MJ, Liebowitz ML, Foa EB. Cognitive behavior therapy and pharmacotherapy for OCD. In: Goodman WK, Maser JD, Rudorfer M, eds. Treatment Challenges in Obsessive-Compulsive Disorder. Mahwah, NJ: Lawrence Erlbaum Associates. In press
8. Pigott TA, Seay S. Biological treatments for obsessive-compulsive disorder: literature review. In: Swinson RP, Antony MM, Rachman S, et al, eds. Obsessive-Compulsive Disorder: Theory, Research, and Treatment. New York, NY: Guilford Publications; 1998:298-326
9. Pato MT, Zoka-Kadouch R, Zohar J, et al. Return of symptoms after desensitization of clomipramine and patients with obsessive-compulsive disorder. Am J Psychiatry 1988;145:1521-1525
10. Van Balkom AJLM, van Dyck R. Combination treatments for obsessive-compulsive disorder. In: Swinson RP, Antony MM, Rachman S, et al, eds. Obsessive-Compulsive Disorder: Theory, Research, and Treatment. New York, NY: Guilford Publications; 1998:349-366
11. Amin MD, Ban TA, Pecknold JC, et al. Clomipramine (Anafranil) and behavior therapy in obsessive-compulsive and phobic disorders. J Int Med Res 1977;5(suppl 5):33-37
12. Neziroglu F. A combined behavioral-pharmacotherapy approach to obsessive-compulsive disorders. In: Oriols J, Ballus C, Gonzalez M, et al, eds. Biological Psychiatry Today. Amsterdam, the Netherlands: Elsevier/North-Holland Press; 1979:591-596
13. Marks IM, Stern RS, Mawson D, et al. Clomipramine and exposure for obsessive-compulsive rituals. Br J Psychiatry 1980;136:1-25
14. Marks IM, Lelliott PT, Basoglu M, et al. Clomipramine, self-exposure and therapist-aided exposure for obsessive-compulsive rituals. Br J Psychiatry 1988;152:522-534
15. Cottraux J, Mollard E, Bouvard M, et al. A controlled study of fluvoxamine and exposure in obsessive-compulsive disorder. Int Clin Psychopharmacol 1990;5:17-30
16. Van Balkom AJL, de Hann E, van Oppen P, et al. Cognitive and behavioral therapies alone versus in combination with fluvoxamine in the treatment of obsessive compulsive disorder. J Nerv Ment Dis 1998;186:492-499
17. Hohagen F, Winkelmann G, Rasche-Rauchle H, et al. Combination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and placebo: results of a multicentre study. Br J Psychiatry 1998; 173(suppl 35):71-78
18. Neziroglu FA, Yarura-Tobias J. Long-term outcome in OCD. In: Syllabus and Proceedings Summary of the 149th Annual Meeting of the American Psychiatric Association; May 8, 1996; New York, NY. Abstract 94B:162
19. Pato MT, Pato CN, Gunn SA. Biological treatments for obsessive-compulsive disorder: clinical applications. In: Swinson RP, Antony MM, Rachman S, et al, eds. Obsessive-Compulsive Disorder: Theory, Research, and Treatment. New York, NY: Guilford Publications; 1998:327-348
20. Steketee G, Chambless DL, Eisen JL. Long-term behavioral treatment for OCD. In: Syllabus and Proceedings Summary of the 149th Annual Meeting of the American Psychiatric Association; May 8, 1996; New York, NY. Abstract 94E:163
21. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale, I: development, use, and reliability. Arch Gen Psychiatry 1989;46;1006-1011
22. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale, II: validity. Arch Gen Psychiatry 1989;46:1012-1016
23. Greist JH, Jefferson JW, Kobak KA, et al. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. Arch Gen Psychiatry 1995;52:53-60
24. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition. New York, NY: Biometric Research, New York State Psychiatric Institute; 1996
25. Kozak MJ, Foa EB. Mastery of Obsessive-Compulsive Disorder: A Cognitive-Behavioral Approach - Therapist Guide. San Antonio, Tex: Graywind Publications; 1997
26. Insel TR, Murphy DL, Cohen RM, et al. Obsessive-compulsive disorder: a double-blind trial of clomipramine and clorgyline. Arch Gen Psychiatry 1983;40:605-612
27. Murphy DL, Pickar D, Alterman IS. Methods for the quantitative assessment of depressive and manic behavior. In: Burdock EI, Sudilovsky A, Gershon S, eds. The Behavior of Psychiatric Patients. New York, NY: Marcel Dekker; 1982
28. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare, publication (ADM 76-338). Rockville, Md: National Institute of Mental Health; 1976:218-222
29. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
30. Pigott TA, L'Heureuz F, Hill JL, et al. A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated OCD patients. J Clin Psychopharmacol 1992;12:11-18
31. Grady TA, Pigott TA, L'Heureux F, et al. A double-blind study of adjuvant buspirone hydrochloride in fluoxetine-treated patients with OCD. Am J Psychiatry 1993;150:819-821
32. McDougle C, Goodman W, Leckman J, et al. Limited therapeutic effect of the addition of buspirone in fluvoxamine-refractory OCD. Am J Psychiatry 1993;150:647-649
33. McDougle C, Price L, Goodman W, et al. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy. J Clin Psychopharmacol 1991;11:175-184
34. Pigott TA, Pato MT, L'Heureux F, et al. A controlled comparison of adjuvant lithium carbonate or thyroid hormone in clomipramine-treated OCD patients. J Clin Psychopharmacol 1991;11:242-248
35. Leonard H, Topol D, Bukstein O, et al. Clonazepam as an augmenting agent in the treatment of childhood-onset obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 1994;33:792-794
36. McDougle CJ, Goodman WK, Leckman JF, et al. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 1994;51:302-308
37. Saxena S, Wang D, Bystritsky A, et al. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J Clin Psychiatry 1996;57:303-306
38. Baer L, Ricciardi J, Keuthen N, et al. Discontinuing obsessive-compulsive disorder medication with behavior therapy [letter]. Am J Psychiatry 1994; 151:1842-1843
39. March JS, Frances A, Carpenter D, et al. Expert Consensus Treatment Guidelines for Obsessive-Compulsive Disorder: a guide for patients and families. J Clin Psychiatry 1997;58(suppl 4):65-72